TxCell Aktie [WKN DE: A1J9E6 / ISIN: FR0010127662]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu TxCell SA

29.02.16		TxCell Launches New Manufacturing Process Development Laboratories and Technology Transfer Academy (Businesswire)
25.02.16		TxCell Announces Successful Key Milestone in the Technology Transfer To CMO Partner MaSTherCell And Updates On Ovasave® Clinical Trial Status (Businesswire)
09.02.16		TxCell To Present Its Latest Cellular Immunotherapy Developments at Leading Investor Conferences in Q1 2016 (Businesswire)
02.02.16		TxCell Announces Revenue and Cash Position as of December 31, 2015 (Businesswire)
06.01.16		TxCell Announces Its Financial Calendar for 2016 (Businesswire)
04.01.16		TxCell: Full-Year Report on Liquidity Contract with Oddo Corporate Finance (Businesswire)
04.01.16		TxCell: monthly information regarding the total number of voting rights and the total number of shares (Businesswire)
22.12.15		TxCell Implements a Two-Year, No-Minimum-Draw Standby Equity Facility (SEF®) (Businesswire)
21.12.15		TxCell admitted to the SRD (Deferred Settlement Service) "Long-only” (Businesswire)
03.12.15		TxCell Signs Strategic Agreement with MaSTherCell for European Manufacturing of Its Cell Therapy Products (Businesswire)
02.12.15		TxCell Re-acquires Full Rights to Its Lead Product Ovasave® (Businesswire)
30.11.15		TxCell Strengthens Management Team with Five New Vice Presidential Appointments (Businesswire)
05.11.15		TxCell: Financial Information for the 3rd quarter of 2015 (Businesswire)
02.11.15		TxCell Secures Key CAR-Treg Patent Through Exclusive Option Agreement with Yeda, the Commercial Arm of World's Recognized Weizmann Institute of Science (Businesswire)
14.10.15		TxCell Reviews Its Manufacturing Strategy to Focus on R&D and Strategic Partnerships - Its Core, High Added Value Businesses (Businesswire)
28.09.15		TxCell to present its cellular immunotherapy developments at leading investor conferences (Businesswire)
22.09.15		TxCell: Financial Results for the First Half of 2015 (Businesswire)
17.09.15		TxCell to Present Its Cellular Immunotherapy Developments at Leading Cell and Ophthalmology Conferences (Businesswire)
14.09.15		TxCell Granted US Orphan Drug Designation for Col-Treg in the Treatment of Chronic Non-Infectious Uveitis (Businesswire)
08.09.15		TxCell Announces Peer-Reviewed Publication of Preclinical Efficacy Results for Col-Treg in Autoimmune Uveitis in a Leading Ophthalmology Journal (Businesswire)
24.08.15		TxCell Consortium Granted €1.28 million for TRUST Project on Process and Clinical Development of Col-Treg for Autoimmune Uveitis Treatment (Businesswire)
04.08.15		TxCell: Financial Information for the First Half of 2015 (Businesswire)
03.08.15		TxCell: Monthly Information Regarding the Total Number of Voting Rights and the Total Number of Shares (Businesswire)
29.07.15		TxCell Appoints MaSTherCell for the Manufacturing of Lead Product Ovasave® (Businesswire)
27.07.15		TxCell Receives Fast Track Designation from FDA for Ovasave® (Businesswire)
22.07.15		TxCell Raises Approx. € 8 Million Through a Private Placement of 10% of Its Common Shares (Businesswire)
29.06.15		TxCell announces FDA acceptance of IND for Ovasave (Businesswire)
24.06.15		TxCell Announces a Temporary Partial Hold of Activities at Its Pilot Manufacturing Unit (Businesswire)
17.06.15		TxCell to participate at the 2015 French Life Sciences Day, New York, US (Businesswire)
28.05.15		TxCell to Deliver Multiple Presentations at 21st ISCT Annual Meeting, Las Vegas, US (Businesswire)
26.05.15		TxCell announces that all resolutions supported by the board of directors were approved during its annual meeting of shareholders (Businesswire)
06.05.15		TxCell: Financial Information for the First Quarter of 2015 (Businesswire)
05.05.15		TxCell presents positive results for Col-Treg in a model of autoimmune uveitis at 2015 ARVO Annual Meeting, Denver, Colorado, US (Businesswire)
28.04.15		TxCell Appoints Stéphane Boissel as Chief Executive Officer and Promotes Miguel Forte to Chief Operating Officer (Businesswire)
23.04.15		TxCell and Trizell Amend Collaboration Agreement to Accelerate Ovasave® Development (Businesswire)
16.04.15		TxCell Strengthens Its Board of Directors by Appointing Dr. David Solomon to Board and as Chair of Sub-Committee (Businesswire)
01.04.15		TxCell 2014 results: strengthening of cash position and development of ASTrIA product platform (Businesswire)
23.03.15		TxCell to Present at Upcoming US and French Investment Conferences (Businesswire)
18.03.15		Key TxCell Patent to Be Granted in the United States for Its Lead Product Ovasave® (Businesswire)
26.02.15		TxCell to Present at ROTH Capital Partners Investor Conference in US (Businesswire)
30.01.15		TxCell announces its financial calendar for 2015 (Businesswire)
29.01.15		TxCell Receives €1 Million Milestone Payment Regarding Ovasave® Collaboration Agreement from Trizell (Businesswire)
27.01.15		TxCell Receives €1.7 million from Bpifrance for Ovasave® Clinical Development in Refractory Crohn’s Disease (Businesswire)
22.01.15		TxCell to Present Its Experience with Cell Therapy at the Cell & Gene Therapy Forum 2015, Washington (Businesswire)
02.01.15		TxCell and Ferring collaboration with lead product Ovasave® to receive additional development expertise from Trizell (Businesswire)
17.12.14		TxCell Receives EU Orphan Drug Designation for Col-Treg in the Treatment of Non-Infectious Uveitis (Businesswire)
04.12.14		TxCell announces start of phase IIb clinical trial with Ovasave® for refractory Crohn’s disease (Businesswire)
07.11.14		TxCell to Present at EU Advanced Therapies Investor Day November 13, in London, UK (Businesswire)
04.11.14		TxCell Reports Revenues for the Third Quarter of 2014 (Businesswire)
28.10.14		TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 22:57
Kaufwert:	EUR
	Hinzufügen Speichern